Fremanezumab to prevent migraineDecember 13, 2018
The USFDA has approved fremanezumab-vfrm(Ajovy) injection for the preventive treatment of migraine in adults,announced Teva Pharmaceuticals.
Fremanezumabis a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. It is the first and only anti-CGRP treatment for the prevention of migrainewith quarterly
(675 mg) and monthly (225 mg) dosing options, Teva said.
Fremanezumab was evaluated in two Phase III, placebo-controlled clinical trials that enrolled patients with disabling migraine and was studied as both a stand-alone preventive treatment and in combination with oral preventive treatments. In these trials, patients experienced a reduction in monthly migraine days during a 12-week period.